Cancer Stem Cell News Volume 10.14 | Apr 14 2021


    2021-04-14 | CSCN 10.13

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.13 – 14 April, 2021

    Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia

    Researchers demonstrated that a key GAS6/AXL axis was highly activated in acute myeloid leukemia patient cells, particularly in stem/progenitor cells.

    The Immunology Podcast is here. Find it wherever you get your podcasts.
    PUBLICATIONSRanked by the impact factor of the journal

    PRDM4 Inhibits Cell Proliferation and Tumorigenesis by Inactivating the PI3K/AKT Signaling Pathway through Targeting of PTEN in Cervical Carcinoma

    Both immunohistochemistry and Western blot assays demonstrated that the expression of PR domain zinc finger protein 4 (PRDM4) in cervical cancer tissues was much lower than that in the normal cervix.

    Full Article

    Lupeol Induces Autophagy and Apoptosis with Reduced Cancer Stem-Like Properties in Retinoblastoma via Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Inhibition

    Lupeol inhibited proliferation and induce apoptosis of retinoblastoma cells, with increased Bax level and decreased Ki67, survivin and Bcl-2 levels.
    [Journal of Pharmacy and Pharmacology]


    Dickkopf-2 Regulates the Stem Cell Marker LGR5 in Colorectal Cancer via HNF4α1

    Scientists report a Wnt ligand, Dickkopf-2 (DKK2) was essential for developing colorectal cancer stemness. Genetic depletion of Dkk2 in intestinal epithelial or stem cells reduced tumorigenesis as well as expression of the stem cell marker genes including Lgr5 in a model of colitis-associated cancer.

    AbstractFull ArticleGraphical Abstract

    TWIST1-Mediated Transcriptional Activation of PDGFRβ in Breast Cancer Stem Cells Promotes Tumorigenesis and Metastasis

    Scientists report that TWIST1, an epithelial-to-mesenchymal transition (EMT) regulated by transcription factors, exhibited positive transcriptional regulation on PDGFRβ promoter, thus identifying PDGFRβ as one of the downstream targets of EMT regulation in breast CSCs.
    [Biochimica Et Biophysica Acta-Molecular Basis of Disease]

    AbstractGraphical Abstract

    Combining Radiation to EGFR and Bcl-2 Blockade: A New Approach to Target Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma

    CSCs had low EGFR expression and, conversely, overexpressed the anti-apoptotic Bcl-2 protein, which is involved in resistance to apoptosis and the invasion/migration capacities of tumor cells.
    [Journal of Cancer Research and Clinical Oncology]


    miR-98-5p Inhibits Gastric Cancer Cell Stemness and Chemoresistance by Targeting Branched-Chain Aminotransferases 1

    The expression of miR-98 in CD44+ gastric cancer stem cells (GCSCs) was verified by RT-PCR. The miR-98 was overexpressed in CD44+ GCSCs by Lentivirus.
    [Life Sciences]


    Long Noncoding RNA SNHG9 Facilitates Growth of Glioma Stem-Like Cells via miR-326/SOX9 Axis

    Glioma stem cells (GSCs) were obtained from glioma cells and referred to as GSC‐87 and GSC‐251, respectively. The interactions between miR‐326 and SNHG9 or SOX9 were analyzed using luciferase reporter assay.
    [Journal of Gene Medicine]


    Pancreatic Cancer Stem Cells May Define Tumor Stroma Characteristics and Recurrence Patterns in Pancreatic Ductal Adenocarcinoma

    Pancreatic ductal adenocarcinoma patients who underwent surgical resection between 01/2012–06/2014 were identified. CD44 and epithelial-specific antigen expression was assessed by immunohistochemistry.
    [BMC Cancer]

    Full Article

    Tumors Are 3D. Shouldn't Your In Vitro Model Be? Learn More.

    Stem Cell Concepts in Myelodysplastic Syndromes: Lessons and Challenges

    The clinical importance of myelodysplastic syndromes (MDS) stem cells has been highlighted through the demonstration of selective persistence of MDS stem cells in patients at complete remission in response to therapy.
    [Journal of Internal Medicine]


    Cancer Stem Cells Targets and Combined Therapies to Prevent Recurrence

    The authors highlight the processes involved in CSCs development and maintenance as well as the current effective therapies based on stem cells, cell-free therapies that involve exosomes and miRNAs, and photodynamic therapy.
    [Life Sciences]

    AbstractGraphical Abstract


    Treovir Announces Positive Results of Phase I Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma

    Treovir, LLC has announced that G207, an oncolytic HSV immunotherapy, was well tolerated with evidence of clinical effectiveness in a Phase I study of 12 pediatric patients with recurrent high-grade glioma.
    [Treovir, LLC (PR Newswire, LLC)]

    Press Release

    Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma

    Arcellx announced that the FDA has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of the company’s ARC-SparX platform of controllable and adaptable cell therapies.

    Press Release

    World Stem Cell Summit

    June 14 – 18, 2021

    > See All Events


    Postdoctoral Research Scientist Positions – Gastrointestinal Oncology

    Columbia University Medical Center – New York, New York, United States

    Postdoctoral Fellow – Pancreatic Liver Metastasis

    Karolinska Institutet – Huddinge, Sweden

    Postdoctoral Fellow – Exosome and Cancer Biology

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Journal Editor – Blood Cancer Discovery and Cancer Immunology

    American Association for Cancer Research – Boston, Massachusetts, United States

    Postdoctoral Fellow – Myeloma Tumor Microenvironment

    Moores Cancer Center – La Jolla, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter